背景:口腔鳞状细胞癌(OSCC)是口腔中最常见的恶性肿瘤,它以预后不良而闻名。不受苯并咪唑1(BUB1)抑制的出芽可能与癌症预后有关;然而,BUB1与OSCC预后之间的具体关系仍未被研究.
方法:使用来自TCGA_OSCC和GSE23558队列的数据分析BUB1的mRNA水平。基于中值BUB1水平,将来自TCGA_OSCC数据集的OSCC样品分为低BUB1表达组和高BUB1表达组。此外,生存分析结果,肿瘤突变负荷(TMB),基因集富集分析(GSEA)途径,比较2组的药物敏感性分析。
结果:根据TCGA_OSCC和GSE23558队列的数据,与健康对照相比,OSCC组织中BUB1mRNA水平显着上调。此外,BUB1的高表达可能是OSCC预后不良的独立指标。此外,高BUB1表达的患者也表现出免疫检查点和TMB水平升高,提示BUB1高表达的患者可能受益于免疫治疗。机械上,发现转录因子ZFP64,TCF3和ZNF281可能与BUB1的启动子区结合,从而调节其基因表达。此外,GSEA结果显示,BUB1在OSCC中的表达与细胞周期和肿瘤相关通路密切相关。药物敏感性分析显示BUB1高表达的患者对吉西他滨可能更敏感,紫杉醇,或伊马替尼。
结论:总的来说,结果表明,高BUB1水平可能与OSCC的不良预后有关,强调其作为OSCC新型预后生物标志物的潜力。
BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common type of malignant tumour in the oral cavity, and it is known for its poor prognosis. Budding uninhibited by benzimidazoles 1 (BUB1) may be related to cancer prognosis; however, the specific relationship between BUB1 and OSCC prognosis remains largely unexplored.
METHODS: The mRNA levels of BUB1 were analysed using data from the TCGA_OSCC and GSE23558 cohorts. OSCC samples from the TCGA_OSCC dataset were divided into low- and high-BUB1 expression groups based on the median BUB1 level. Furthermore, results of survival analysis, tumour mutation burden (TMB), gene set enrichment analysis (GSEA) pathways, and drug-sensitivity analysis were compared between the 2 groups.
RESULTS: Based on the data from the TCGA_OSCC and GSE23558 cohorts, BUB1 mRNA levels were significantly upregulated in OSCC tissues compared to healthy controls. Moreover, high expression of BUB1 may serve as an independent indicator of poor prognosis in OSCC. Additionally, patients with high BUB1 expression also exhibited increased levels of immune checkpoints and TMB, suggesting that patients with high BUB1 expression may benefit from immunotherapy. Mechanistically, transcription factors ZFP64, TCF3, and ZNF281 were found to potentially bind to the promoter region of BUB1, thereby regulating its gene expression. Furthermore, GSEA results showed that BUB1 expression was closely related to cell cycle and tumour-related pathways in OSCC. Drug-sensitivity analysis showed that patients with high BUB1 expression may be more sensitive to gemcitabine, paclitaxel, or imatinib.
CONCLUSIONS: Collectively, results demonstrated that high BUB1 levels may be related to a poor prognosis of OSCC, highlighting its potential as a novel prognostic biomarker for OSCC.